Investment Plan 2008-2012
The Board of Directors has approved a plan for investing in production and
plasma collection facilities that will position the Company as an industry
leader for the foreseeable future.
BARCELONA, Spain, Oct. 30 /CNW/ -- Grifols' Board of Directors, which met
on October 23, 2007 in Los Angeles, California, has approved a euro 400
million investment plan that will be carried out between now and the year
2012. Among other things, the new investments will be to increase capacity for
plasma fractionation and purification, as well as to increase plasma supply.
Within the scope of the approved investment plan, euro 230 million will
be designated for ensuring growth in production and sales during the 2008-2012
period, and the remaining euro 170 million will support growth from 2013
onward. This will allow the company to prepare for sustained growth over the
next 8 to 10 years.
In order to ensure growth through the year 2012, Grifols will invest euro
230 million in its production facilities in Spain and the USA.
Investments to be made in the Spanish facilities include euro 130 million
for the construction of a new fibrin glue (biological adhesive) production
facility and expansion of the albumin and coagulation factor VIII purification
areas. Albumin and coagulaton factor VIII are two of the principal plasma
proteins that Grifols markets.
In the USA, euro 100 million will be invested in the Los Angeles
facilities for the completion of the purification and sterile filling areas
for coagulation factors (such as Factor VIII), the opening of new plasma
collection centers and the construction of a new analytical laboratory in
Austin, Texas. This laboratory, which will be located near Grifols existing
US-based laboratory, will allow the company to handle the growing amount of
plasma samples to be analyzed. Additionally, the new laboratory will serve
the strategic purpose of providing Grifols an alternate testing location.
Forty-two percent (42%) of the 2008-2012 investment plan will be set
aside for ensuring growth after the year 2013.
These investments, designated for ensuring Grifols' growth from the year
2013 onward, will also be allocated to the Spanish and US facilities. Sixty
million Euros will be invested in facilities located in Barcelona, Spain
mainly for the purpose of doubling current plasma fractionation capacity from
2 million liters in 2007 to 4 million liters in 2013. In the USA, the company
will invest euro 110 million at its current location in Los Angeles,
California to build a new Flebogamma DIF(R) (IVIG) production facility. The
new facility will be designed to match the existing Flebogamma DIF(R) facility
in Barcelona, Spain. Grifols will also continue to expand the number of plasma
collection centers it owns and operates in the USA.
The investment plan takes into account the fact that biological
production facilities require an average of five years from the time the
investment is approved to the time regulatory authorizations (FDA, EMEA, etc.)
are likely to be obtained for the marketing of products.
All of the engineering projects related to the investments to be carried
out at the various Grifols' facilities have already been designed and will be
executed by Grifols Engineering S.A., a wholly owned subsidiary of Grifols
that designs, fabricates and installs custom production equipment for the
Grifols' euro 400 million five-year investment plan is expected to be
funded with both internal and external resources.
Grifols is a Spanish holding company specializing in the pharmaceutical-
hospital industry, with a presence in more than 90 countries. Since May of
2006 its shares have been traded on the Spanish Stock Exchange (Mercado
Continuo Espanol) and it is included in the Spanish index of medium
capitalization firms (IBEX MEDIUM CAP). It is currently the leading European
company in the plasma therapies industry and the fourth-largest producer in
the world. In the coming years, Grifols will leverage its market leadership as
a vertically integrated company through past and future investments that will
allow it to ensure its plasma supply through 77 plasmapheresis centers located
in the United States, while at the same time expanding fractionating capacity
with production facilities in Barcelona and Los Angeles, capable of meeting
the growing market demand.
For further information:
For further information: Raquel Lumbreras, Duomo Comunicacion, mobile
phone: +659 57 21 85, firstname.lastname@example.org ; or Grifols
Press Office, Tel. +34 91 311 92 90, or Fax. +34 91 311 92 89 Web Site: